| Market Capitalization (Millions $) |
2,083 |
| Shares
Outstanding (Millions) |
105 |
| Employees |
41 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-34 |
| Cash Flow (TTM) (Millions $) |
63 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Trillium Therapeutics Inc is a clinical stage biotechnology company that is focused on developing innovative therapies to treat cancer. The company is headquartered in Mississauga, Ontario, Canada and was founded in 200 Trillium's pipeline includes multiple compounds that target various types of cancer, including hematologic malignancies and solid tumors.
The company's lead product candidate, TTI-621, is a novel biologic designed to target CD47, a protein that is overexpressed in many different cancers. CD47 acts as a "don't eat me" signal to macrophages, a type of immune cell that is responsible for identifying and destroying cancer cells. TTI-621 is designed to block CD47, allowing macrophages to recognize and attack cancer cells more effectively.
Trillium is also developing TTI-622, a second generation CD47-blocking biologic, which has shown improved pharmacokinetic properties compared to TTI-62 In addition, the company is developing a pipeline of clinical stage assets that target various other pathways involved in cancer growth and metastasis.
Trillium's management team has extensive experience in the biotech industry, and the company has established partnerships and collaborations with leading academic and industry partners. The company is committed to advancing innovative cancer therapies and improving outcomes for patients with cancer.
Company Address: 100 CambridgePark Drive Cambridge 2140 MA
Company Phone Number: 595-0627 Stock Exchange / Ticker: NASDAQ TRIL
|
0.000%